These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38462823)

  • 101. Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial.
    Hammond NE; Finfer SR; Li Q; Taylor C; Cohen J; Arabi Y; Bellomo R; Billot L; Harward M; Joyce C; McArthur C; Myburgh J; Perner A; Rajbhandari D; Rhodes A; Thompson K; Webb S; Venkatesh B;
    Intensive Care Med; 2020 Sep; 46(9):1696-1706. PubMed ID: 32676679
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A Retrospective Observational Study of Quality of Life in a Northern Greece Population of People with Haemophilia.
    Moka E; Ntova Z; Gavriilaki E; Kotsiou N; Chissan S; Papadopoulou T; Vakalopoulou S
    Life (Basel); 2024 May; 14(6):. PubMed ID: 38929680
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Bleeds and resource use in hemophilia B: retrospective observational study.
    Young L; Ban L; Chen Y; Fogarty PF
    Am J Manag Care; 2024 May; 30(5):e157-e164. PubMed ID: 38748916
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
    Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
    J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial.
    Coppens M; Pipe SW; Miesbach W; Astermark J; Recht M; van der Valk P; Ewenstein B; Pinachyan K; Galante N; Le Quellec S; Monahan PE; Leebeek FWG;
    Lancet Haematol; 2024 Apr; 11(4):e265-e275. PubMed ID: 38437857
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B.
    Klamroth R; Bonner A; Gomez K; Monahan PE; Szafranski K; Zhang X; Walsh S; Wang D; Yan S
    Haemophilia; 2024 Jan; 30(1):75-86. PubMed ID: 37902714
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.
    Pipe SW; Leebeek FWG; Recht M; Key NS; Castaman G; Miesbach W; Lattimore S; Peerlinck K; Van der Valk P; Coppens M; Kampmann P; Meijer K; O'Connell N; Pasi KJ; Hart DP; Kazmi R; Astermark J; Hermans CRJR; Klamroth R; Lemons R; Visweshwar N; von Drygalski A; Young G; Crary SE; Escobar M; Gomez E; Kruse-Jarres R; Quon DV; Symington E; Wang M; Wheeler AP; Gut R; Liu YP; Dolmetsch RE; Cooper DL; Li Y; Goldstein B; Monahan PE
    N Engl J Med; 2023 Feb; 388(8):706-718. PubMed ID: 36812434
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: Results from the phase III HOPE-B trial 2 years after gene therapy.
    Itzler R; Buckner TW; Leebeek FWG; Miller J; Recht M; Drelich D; Monahan PE; Pipe SW
    Haemophilia; 2024 May; 30(3):709-719. PubMed ID: 38462823
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency).
    Sekayan T; Simmons DH; von Drygalski A
    Expert Opin Biol Ther; 2023; 23(12):1173-1184. PubMed ID: 37962325
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Etranacogene Dezaparvovec: First Approval.
    Heo YA
    Drugs; 2023 Mar; 83(4):347-352. PubMed ID: 36802324
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
    Castaman G; Coppens M; Pipe SW
    Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Etranacogene dezaparvovec for hemophilia B gene therapy.
    Thornburg CD
    Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
    [TBL] [Abstract][Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.